Intellia Therapeutics reports Q2 financial results, operational highlights on Aug 7.

• Intellia Therapeutics reports Q2 2025 financial results and operational highlights. • Conference call on August 7, 2025 at 8 a.m. ET. • Dial 1-833-316-0545 (US) or 1-412-317-5726 (int'l) to join. • Live webcast available at intelliatx.com. • Replay available from August 7, 2025, at 12 p.m. ET. • Intellia Therapeutics is a clinical-stage gene editing company.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has scheduled its second quarter 2025 earnings conference call for August 7, 2025, at 8:00 a.m. ET. The company will discuss its financial results and operational highlights during the call. Investors can join the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will be available, and a replay will be accessible through Intellia's website after 12 p.m. ET on the same day [2].

Intellia Therapeutics is a clinical-stage gene editing company that focuses on developing curative therapeutics using CRISPR-based technologies. The company's in vivo programs include NTLA-2001, NTLA-2002, and NTLA-3001, which are in various stages of clinical trials for the treatment of transthyretin amyloidosis, hereditary angioedema, and alpha-1 antitrypsin deficiency associated lung disease, respectively [1].

In its last quarter, Intellia reported a revenue of $16.63 million, exceeding analyst expectations, despite posting a loss of $1.10 earnings per share. The company's revenue was down 42.6% year-over-year, and it had a negative net margin of 1,154.10% and a negative return on equity of 56.06% [1].

The company's stock has seen increased interest from analysts and institutional investors. Several research firms have issued reports on NTLA, with most analysts rating the stock as a "buy" or "outperform." Institutional investors and hedge funds own 88.77% of the company's stock [1].

Intellia Therapeutics is expected to post -5.07 EPS for the current year, according to analyst estimates [1]. The company's fifty-day moving average is $9.96, and its 200-day moving average is $9.38. The stock has a market cap of $1.41 billion, a PE ratio of -2.60, and a beta of 2.21 [1].

Investors and financial professionals are encouraged to tune in to the conference call and webcast to gain insights into Intellia Therapeutics' performance and future prospects.

References:
[1] https://www.marketbeat.com/instant-alerts/intellia-therapeutics-nasdaqntla-trading-69-higher-time-to-buy-2025-07-25/
[2] https://www.stocktitan.net/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-ii7jswflkp01.html